Summary: Granules India Limited, a pharmaceutical company, is expected to see a strong growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines such as controlled substances, complex generics, and oncology launches is seen as a key driver of its future success.
Disclaimer: The views expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to seek advice from certified experts before making any investment decisions.
In the latest news, Granules India Limited has been recognized for its strong growth potential in the Indian pharmaceutical market. The company is expected to see a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Original news source: Moneycontrol.com
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-2029 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is poised for a significant increase in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-29 Estimates). The company's focus on growth engines, such as controlled substances, complex generics, and oncology launches, is seen as a key driver of its future success.
Indian pharmaceutical company, Granules India Limited, is set to experience a remarkable growth in revenue, EBITDA, and PAT (Profit After Tax) in FY26-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-2029E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 2026-29E (Forecasted Financial Year 20